Development of a salt-based nanomedicine for non-muscle invasive bladder cancer

Active Grant Awarded

Award ID
R42CA262399
Recipient
Awarding agency
Obligated
$937,492

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 10% complete
Place of performance
Athens, GA 30602, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded Athna Biotech Inc. $937,492 on September 10, 2026, as Grant R42CA262399 under Assistance Listing 93.395, Cancer Treatment Research. The program funds the development and evaluation of improved cancer treatment methods, including surgery, radiotherapy, chemotherapy, and molecularly targeted therapies.

The award funds development of AB-002, a non-viral, lipid-coated sodium chloride nanoparticle intravesical therapy for non-muscle invasive bladder cancer (NMIBC). The source states that the nanoparticles enter cancer cells through endocytosis, release sodium and chloride ions that induce osmotic lysis, and trigger immunogenic cell death. The source describes the therapy as aimed at BCG-unresponsive NMIBC, a population where cystectomy is the recommended alternative. The source reports that Phase I work developed a robust method to synthesize AB-002 and demonstrated its ability to induce cancer cell death.

The obligated amount is $937,492, and the period of performance runs from the September 10, 2026 award date to an ultimate completion date of August 31, 2028. Work is performed at Athens, GA 30602, USA. The assistance type is a grant. The source does not name any sub-recipients.

Description

Abstract
Bladder cancer is the tenth most common cancer globally, with over 600,000 new cases and more than 200,000 deaths reported in 2022. Approximately 75% of cases are classified as non-muscle invasive bladder cancer (NMIBC). Due to its high recurrence rate, NMIBC is among the most expensive cancers to manage on a per-patient basis, as IT requires lifelong surveillance and prolonged treatment. For patients with intermediateand high-risk NMIBC, the standard of care is transurethral resection of the bladder tumor (TURBT), followed by intravesical bacille calmette-guérin (BCG) therapy. However, about one-third of patients do not respond to BCG, and an additional 10-15% are unable to tolerate IT. For these patients, cystectomy is the recommended option, but IT carries considerable morbidity and a substantial impact on quality of life. Therefore, there is an urgent need for effective, bladder-sparing therapies for BCG-unresponsive NMIBC. Athna biotech, INC. Is developing AB-002, a novel, non-viral oncolytic intravesical therapy for NMIBC. AB-002 consists of lipid-coated sodium chloride nanoparticles, and they are delivered intravesically and enter bladder cancer cells via endocytosis. Once internalized, the nanoparticles break down, releasing sodium and chloride ions, elevating intracellular solute concentrations, thereby inducing osmotic lysis of cancer cells. Moreover, AB- 002 triggers immunogenic cell death and promotes antigen-specific immune responses, facilitating long-term tumor suppression. Following treatment, the nanoparticles degrade into ions that are safely excreted in the urine, causing no cumulative or systemic toxicity. Overall, AB-002 represents a promising treatment for NMIBC with an innovative mechanism of action and a favorable safety profile. In phase I, we developed a robust method to synthesize AB-002, demonstrated its ability to induce cancer cell death and activate immune responses, and showed that intravesically delivered AB-002 is well tolerated. Building on these promising results, this phase II project will focus on key steps toward clinical translation, including establishing good laboratory practice (GLP) manufacturing of AB-002, evaluating its efficacy in additional bladder cancer models, and conducting IND-enabling studies. The use of animal models is essential for this work, as no in vitro or in silico systems can adequately replicate intravesical delivery, the complex tumor-immune microenvironment, or the in vivo processes governing nanoparticle degradation, clearance as ionic species, and host toxicity following treatment.

Quick answers

Who received award R42CA262399?

R42CA262399 was awarded to Athna Biotech Inc. by National Cancer Institute (National Institutes of Health) on September 10, 2026.

How much is award R42CA262399 worth?

$937,492 has been obligated on R42CA262399.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award